Skip to content

Exploratory study on glucose metabolism by continuous intake of plant-extracted food

NR2022001 - NR2022001

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000048820
Enrollment
20
Registered
2022-09-01
Start date
2022-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

Intake of 2 packets of test food per day for 12 weeks

Sponsors

NIKODERM RESEARCH INC.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Males and females aged 30 to 65 at the time of informed consent 2) Those with a BMI of 18.5 kg/m2 or more and less than 30.0 kg/m2 3) Subjects who have received a sufficient explanation of the purpose and content of the study and have signed a consent form before the start of the study

Exclusion criteria

Exclusion criteria: 1) bowel disease (irritable bowel syndrome, Crohn's disease), liver disease, kidney disease, cardiovascular disease (brain and heart), diabetes, dyslipidemia, hypertension, epileptic seizures, sleep apnea, and other chronic diseases Those who are undergoing drug treatment due to past medical history or current medical history 2) Those who have a history of gastrointestinal surgery 3) Subjects who regularly use health foods that may affect inspection items 4) Subjects who cannot stop taking pharmaceuticals, quasi-drugs, and health foods from obtaining consent until the end of the study 5) heavy alcohol drinker 6) Those who have extremely irregular eating habits 7) Shift workers or late-night workers 8) a person who regularly uses some kind of drug 9) Subjects who plan to receive treatment during the intake period of the test food 10) Subjects with perennial atopic dermatitis or rhinitis 11) Those who have a history of anaphylactic shock in the past 12) Subjects judged inappropriate by the investigator and subinvestigator

Design outcomes

Primary

MeasureTime frame
Area under the curve of blood glucose level

Secondary

MeasureTime frame
Fasting blood glucose level Postprandial blood glucose level (30, 60, 90, 120 min) maximum blood glucose level

Countries

Japan

Contacts

Public ContactAkihiro Fujimoto

Medical Corporation Kyoso-kai AMC Nishi-Umeda Clinic Department of Clinical Research Center

fujimoto@amc-clinic.jp06-4797-5660

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026